NASDAQ : XGN
Exagen Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 8.59 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 208.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 208.10M |
| Enterprise Value | 211.16M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 24.23M |
| Shares Outstanding | 24.23M |
| Shares Change (YoY) | +23.90% |
| Shares Change (QoQ) | +1.30% |
| Owned by Insiders (%) | 19.22% |
| Owned by Institutions (%) | 32.93% |
| Float | 13.47M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.93 |
| Forward PS | 2.71 |
| PB Ratio | 17.01 |
| P/TBV Ratio | 17.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.18 |
| Quick Ratio | 2.75 |
| Debt / Equity | 2.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.58 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -113.82% |
| Return on Assets (ROA) | -14.92% |
| Return on Invested Capital (ROIC) | -19.16% |
| Return on Capital Employed (ROCE) | -34.33% |
| Weighted Average Cost of Capital (WACC) | 15.76% |
| Revenue Per Employee | $323,282 |
| Profits Per Employee | -$86,014 |
| Employee Count | 220 |
| Asset Turnover | 1.29 |
| Inventory Turnover | 7.45 |
Taxes
| Measure | Value |
|---|
| Income Tax | 50,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.12 |
| 52-Week Price Change | -27.51% |
| 50-Day Moving Average | 7.92 |
| 200-Day Moving Average | 5.03 |
| Relative Strength Index (RSI) | 58.62 |
| Average Volume (20 Days) | 358,766 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 673,850 |
| Short Previous Month | 704,634 |
| Short % of Shares Out | 2.78% |
| Short % of Float | 5.00% |
| Short Ratio (days to cover) | 2.06 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 71.12M |
| Gross Profit | 41.70M |
| Operating Income | -13.21M |
| Pretax Income | -18.87M |
| Net Income | -18.92M |
| EBITDA | -10.77M |
| EBIT | -13.21M |
| Loss Per Share | -$0.80 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 24.59M |
| Total Debt | 27.66M |
| Net Cash | -3.07M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 12.22M |
| Book Value Per Share | 0.50 |
| Working Capital | 29.40M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -6.50M |
| Capital Expenditures | -1.09M |
| Depreciation & Amortization | 2.44M |
| Net Borrowing | -1.41M |
| Free Cash Flow | -7.59M |
| FCF Per Share | -$0.31 |
Margins
| Measure | Value |
|---|
| Gross Margin | 58.64% |
| Operating Margin | -18.58% |
| Pretax Margin | -26.54% |
| Profit Margin | -26.61% |
| EBITDA Margin | -15.15% |
| EBIT Margin | -18.58% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -23.90% |
| Shareholder Yield | -23.90% |
| Earnings Yield | -9.31% |
| FCF Yield | -3.65% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.57 |
| Price Target Difference | 23.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 11.37% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.26 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |